BSG and pulmonary fibrosis: Meplazumab, a CD147 antibody, was able to slow the development of lung fibrosis caused by SARS-CoV-2 by preventing the buildup of activated fibroblasts and the generation of extracellular matrix (ECM) proteins [266].